Friday, May 06, 2022 12:49:43 PM
The criminal Dr JJ could have joined RLF with their ACER sub and the Nrx drugs to become a Real pharma. But NO, personal greed, incompetent CT design and implementation by this criminal has delayed and then ruined most possibilities.
Sorry for the venting to all still invested. I lost on RLF too. Worst slime ball POS I've ever heard of. GEM must be so happy, they've been filling his pockets for years before Avitadil which is better and safer than Paxlovid Criminal incompetence on so many levels, IMO.
...GLTA...elsewhere...
Sorry for the venting to all still invested. I lost on RLF too. Worst slime ball POS I've ever heard of. GEM must be so happy, they've been filling his pockets for years before Avitadil which is better and safer than Paxlovid Criminal incompetence on so many levels, IMO.
...GLTA...elsewhere...
Recent NRXP News
- NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 • GlobeNewswire Inc. • 05/28/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System • GlobeNewswire Inc. • 05/27/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/18/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality • GlobeNewswire Inc. • 05/07/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 04/06/2026 11:00:00 AM
- Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 03/17/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date • GlobeNewswire Inc. • 01/16/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval • GlobeNewswire Inc. • 01/14/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions • GlobeNewswire Inc. • 01/05/2026 11:57:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion • GlobeNewswire Inc. • 12/18/2025 12:05:00 PM
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation • GlobeNewswire Inc. • 12/03/2025 12:00:00 PM
- NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine • GlobeNewswire Inc. • 12/02/2025 01:30:00 PM
